---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-22-026890"
form_type: "8-K"
ticker: "DYAI"
cik: "0001213809"
company_name: "DYADIC INTERNATIONAL INC"
filed_at: "2022-11-10T23:59:59+00:00"
generated_at: "2026-06-21T22:20:37.461555+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Dyadic Q3 net loss $1.8M; SAHPRA clears Phase 1 COVID-19 vaccine trial

## Summary
- Net loss $1.809M ($0.06/share); revenue $0.88M vs $0.693M YoY increase.
- Cash and investments $14.2M; expects to fund operations into 2024.
- SAHPRA approved Phase 1 trial for DYAI-100 COVID-19 RBD booster; enrollment planned later 2022.
- R&D expenses fell to $0.744M from $1.902M YoY as pre-clinical activities wound down.
- 9x improvement in Nivolumab expression to 22.3 g/L; livestock antigen titers up to 10 g/L.

## SEC filing metadata
- accession: 0001437749-22-026890
- form_type: 8-K
- ticker: DYAI
- cik: 0001213809
- company_name: DYADIC INTERNATIONAL INC
- filed_at: 2022-11-10T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1213809/000143774922026890/0001437749-22-026890-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1213809/000143774922026890/dyai20220814_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-22-026890
- JSON: https://secwatch.observer/filing/0001437749-22-026890.json
- Plain text: https://secwatch.observer/filing/0001437749-22-026890.txt

## Key facts
- Earnings Releases
  DYADIC INTERNATIONAL INC reported financial results for the quarter ended September 30, 2022.
  - Period: the quarter ended September 30, 2022
  - Result: reported results
  source text: On November 10, 2022, Dyadic International, Inc. ("Dyadic”) issued a press release announcing its results for the quarter ended September 30, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1213809/000143774922026890/0001437749-22-026890-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.